Meningioma Clinical Trials 2024

What are the top hospitals conducting meningioma research?

When it comes to clinical trials focused on meningioma, several top hospitals are making significant strides in research and treatment. In Boston, Massachusetts General Hospital leads the pack with five ongoing trials dedicated to this brain tumor. With a history of seven previous meningioma trials since their first recorded study in 2009, they have been at the forefront of advancing knowledge and therapies for this condition. Northwestern University in Chicago is also actively contributing to the fight against meningioma with five current trials and an equal number of past studies dating back to 2009.

Moving westward, Children's Hospital Colorado in Aurora has emerged as a leading institution for meningioma research. Although they recently began studying this specific brain tumor in 2020, their commitment is evident with two active clinical trials already underway. Meanwhile, back on the East Coast at Dana-Farber Cancer Institute in Boston, researchers are focusing on finding innovative approaches to treat meningioma through two ongoing trials and eight completed studies since their inaugural trial took place in 2004.

Lastly but certainly not leastly,Cincinnati Children's Hospital Medical Center plays a crucial role by furthering our understanding of meningiomas through its dedication towards conducting progressive experiments; currently engaging them into tackling two significant tests while having previously conducted three such ventures all starting from their very first endeavor way back during2004.

These esteemed hospitals represent beacons of hope for patients affected by meningiomas—a type of brain tumor that can cause various symptoms depending on its location—and signify how collaboration between medical professionals and institutions can lead us closer to effective treatments or even potential cures for these complex conditions impacting countless lives worldwide

Which are the best cities for meningioma clinical trials?

When it comes to meningioma clinical trials, certain cities stand out as leaders in research and development. In Boston, Massachusetts, there are 12 active trials focusing on treatments like Pembrolizumab, AZD2014, and REC-2282. Chicago, Illinois follows closely behind with 10 ongoing studies exploring options such as FAK Inhibitor GSK2256098, Radiation Therapy, and LUTATHERA® (Lutetium Lu 177 dotatate). Los Angeles, California also has 10 active trials investigating therapies including Radiation Therapy and Brigatinib. Lastly, Miami, Florida and New york City each have eight active trials examining various treatments for meningioma. These cities offer individuals battling this condition access to cutting-edge clinical trials that may lead to significant advancements in care.

Which are the top treatments for meningioma being explored in clinical trials?

Exciting advancements are taking place in the realm of meningioma treatments, with several promising options currently being explored in clinical trials. Leading the way is pembrolizumab, which is currently involved in two active trials and has a total of three all-time trials dedicated to meningioma since its introduction in 2017. Another noteworthy contender is cabozantinib, showing promise with one ongoing trial and one all-time trial for meningioma since its debut in 2022. Additionally, LUTATHERA® (Lutetium Lu 177 dotatate) and the CONVIVO system have also entered the arena recently with one active trial each, further fueling hope for improved outcomes in patients fighting this rare brain tumor. These innovative treatments hold great potential for transforming the landscape of meningioma care.

What are the most recent clinical trials for meningioma?

Exciting advancements in clinical trials for meningioma offer hope and new possibilities for patients. One notable study involves the use of hyperpolarized 13C pyruvate and Magnetic Resonance Imaging, providing valuable insights into the diagnosis and treatment of this condition. Another trial explores LUTATHERA® (Lutetium Lu 177 dotatate), a targeted therapy that shows promise in both Phase 1 and Phase 2 trials. Additionally, ongoing research emphasizes tailored approaches for high-grade meningiomas to optimize patient care. The investigation of REC-2282 as well as cabozantinib further expands our understanding of potential treatments for meningioma at different stages. These recent clinical trials bring us closer to improved outcomes and an increased quality of life for individuals affected by this complex brain tumor.

What meningioma clinical trials were recently completed?

Recently, several clinical trials investigating meningioma have reached completion, providing valuable insights into potential treatments for this challenging brain tumor. One notable trial was conducted by the National Cancer Institute (NCI), focusing on the efficacy of a novel therapy called AR-42. Another significant study, sponsored by Novartis Pharmaceuticals, evaluated the use of an investigational drug known as ribociclib in combination with radiation therapy. These advancements in meningioma research bring hope to patients and highlight ongoing efforts to improve outcomes for those affected by this condition.